Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top ...

"Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe ...

Beam Therapeutics (NASDAQ: BEAM) , a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated da ...

Screening can now determine their risk for an ever-growing list of conditions — including ones we can’t do much about.

“Sickle cell disease is a devasting ... at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing ...

BEAM-101 is an investigational genetically modified ex vivo cell therapy for ... at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable ...

G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging.

The child will need to be monitored throughout his life, but researchers said the treatment’s success indicates that other ...

A CRISPR treatment seems to have been effective for a baby’s devastating disease, but it is not clear whether such bespoke therapies can be widely applied ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...

Scientists were able to create a bespoke treatment for KJ Muldoon’s rare genetic disorder within six months. It could be a ...

Two groundbreaking biotechnology advances are fundamentally altering human health and food production in 2025, moving from ...